As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...
Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.
What major challenge of traditional CAR-T does the in vivo alleviate/address? In addi | Dr Adrian Bot, Capstan Therapeutics, ...
The Chosun Ilbo on MSN
In vivo CAR-T: Game-changing single injection for cancer
A method called **‘in vivo CAR-T (in vivo CAR-T·in vivo CAR-T)’** that directly alters immune cells within the body with a single injection is recently transforming the cancer treatment market. This ...
BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug ...
SAN JOSE, Calif., Nov. 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...
The last time I wrote about Allogene Therapeutics, Inc. (ALLO) it was in a Seeking Alpha article entitled "Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products." I noted the ...
CAR T-cell therapies are individualized treatments approved for multiple hematologic malignancies, with improved management of adverse effects over time. Access to CAR T-cell therapies is limited by ...
Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...
Could CAR-T, the immunotherapy that has transformed treatment for some cancers, hold promise for Alzheimer’s? In the February 9 PNAS, scientists led by Jonathan Kipnis at Washington University in St.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results